Meet John Hammitt, HITLAB’s new executive director. John has been at the forefront of technology solutions across business and healthcare sectors for decades.
“John is a natural born global digital health leader, one of only a handful of those working in the field for the past few decades. He sees ways to innovate and improve on the status quo in everything he encounters,” said Stan Kachnowski, HITLAB chair. “From ideation and design, to execution and scale, John has decades of experience turning great ideas into reality.”
A Lifelong Innovator
Early in his 4-decade career, John brought his innovation mindset to companies as diverse as eJNJ, Morton-Thiokol, Pillsbury, and United Technologies, serving in the role of global CIO in combination with other innovation-focused responsibilities. In 1997, John entered the healthcare space and never left.
“I found the industry that inspired passion and where I could have the most positive impact on the greatest number of individual lives,” John says. From 1997 until his retirement in 2007, he held a number of leadership positions at Johnson & Johnson, in the area of healthcare innovation and leveraging technology to enhance best practices. He served as global CIO and vice president for pharmaceuticals and diagnostics, vice president for global networking and computing services and, simultaneously, as president of eJNJ, a strategic business-development company focused on finding and building new, emerging and innovative technology-based healthcare solutions for Johnson and Johnson’s family of companies.
From HITLAB Senior Fellow to Executive Director
After eJNJ, John found himself advising startups in the areas of healthcare and digital innovation. He helped lead several venture-backed startups, including Hx Technologies, and Secure-i. He founded Sunrise Advisors and also served as a board member to QuickStart Global. Additionally, along with a handful of partners, he established Healthper and UV Therapeutics.
In 2015, he joined HITLAB as a senior fellow and has played a crucial role in advising sponsors regarding best-practices for pursuing technology-enabled health innovations, helping digital health innovation teams overcome crucial barriers that add risk to their innovation strategies, and establishing ways for quickly verifying innovative healthcare ideas with evidence-based discipline.
“HITLAB is an extraordinary place where evidence-based, digital health insights help form solutions impacting lives of patients around the world,” John says. “I’m thrilled to be joining HITLAB’s leadership team during this time of accelerating growth and broadening influence. Our goal is simple: find results that through rapid market diffusion will improve the lives of as many patients as possible.”
John will make one of his first public appearances as HITLAB executive director at the 2017 HITLAB Symposium: Palo Alto, sponsored by Novo Nordisk on October 23. As one of the event’s featured speakers, John will outline his vision for the future of digital health.
“Over two decades, HITLAB has become a leading source of knowledge, insights and advice about digital technology’s influence on healthcare and patients,” John says. “Building from that foundation, I’m excited about the opportunity to accelerate HITLAB’s growth and broaden its impact.”